5 big analyst AI moves: Nvidia target upped to $240, Oracle gets a Sell rating
Investing.com - TD Cowen has reiterated its Buy rating and $115.00 price target on Boston Scientific (NYSE:BSX), currently valued at $144 billion, ahead of the company’s upcoming investor day on September 30, 2025. The strong Buy consensus among analysts is supported by InvestingPro data showing robust financial health metrics.
The firm expects Boston Scientific to announce a long-range plan (LRP) targeting 10-12% sales growth through 2028, which would exceed the approximately 10% growth analysts are currently projecting for the next three years.
This anticipated growth target represents an upgrade from the 8-10% revenue growth outlined in the company’s 2023 LRP, reflecting Boston Scientific’s commitment to being the top performer in the medical technology sector.
TD Cowen believes the investor day will highlight several key products, including the Watchman’s Champion trial, the Farapulse franchise, and the SoniVie renal denervation system.
The firm also expects Boston Scientific to reaffirm its 2025 outlook during the event, potentially reducing risk ahead of its third-quarter earnings report and guidance update in October.
In other recent news, Boston Scientific reported several key developments. Elutia Inc. announced it will sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88 million in cash, with the transaction expected to close in the fourth quarter of 2025. Analysts at Oppenheimer upgraded Boston Scientific’s stock rating to Outperform, setting a price target of $125.00, citing the company’s strong execution and strategic mergers and acquisitions, especially in the electrophysiology sector. Meanwhile, Needham reiterated its Buy rating with a $121.00 price target, highlighting potential growth from Boston Scientific’s acquisition of Bolt Medical and the upcoming launch of Bolt’s laser-based intravascular lithotripsy system. Stifel released a new analysis of electrophysiology hospital purchasing data for the third quarter of 2025, which remains a focal point for Boston Scientific. Additionally, Needham expects the company to provide updates on its business units, product launches, and financial targets at the upcoming investor day. These recent developments indicate Boston Scientific’s strategic focus on growth through acquisitions and product innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.